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Minireview
Proteomics of Hepatocellular Carcinoma
in Chinese Patients
John M. Luk and Angela M. Liu
Abstract
Hepatocellular carcinoma (HCC) is a malignant tumor of liver that causes approximately half a million deaths
each year, of which over half of the cases are diagnosed in China. Because of its asymptomatic nature, HCC is
usually diagnosed at late and advanced stages, for which there are no effective therapies. Thus, biomarkers for
early detection and molecular targets for treating HCC are urgently needed. With the advent of high-throughput
omics technologies, we have begun to mine the genomics and proteomics information of HCC, and most
importantly, these data can be integrated with clinical annotations of the patients. Such new horizons of inte-
grated profiling informatics have allowed us to search for and better identify clinically useful biomarkers and
therapeutic targets for cancers including HCC. Capitalizing the large clinical samples cohort (over 100 pairs of
tumor and matched adjacent nontumor tissues of HCC), we herein discuss the use of proteomics approach to
identify biomarkers that are potentially useful for (1) discrimination of tumorous from nonmalignant tissues, (2)
detection of small-sized and early stage of HCC, and (3) prediction of early disease relapse after hepatectomy.
The Unmet Medical Issues
in Hepatocellular Carcinoma (HCC)
HCC is a prevalent malignancy with poor outcome.About 600,000 new cases are diagnosed each year,
among which 55% are identified in China, and increasing in-
cidence is observed in Western countries. Globally, HCC re-
mains the fifthmost common cause of cancermortality (Parkin
et al., 2005). The major risk factors for HCC are cirrhosis re-
lated to chronic hepatitis B or C viral infection, environmental
poisoning (e.g., alfatoxin), alcohol abuse, and genetic alter-
ation (Pang et al., 2008). HCC usually progresses slowly and is
asymptomatic in early stages. The most common curative
treatments for HCC are surgical resection and liver trans-
plantation; however, only 10–20% of the patients are eligible
for the surgical intervention, and patients who had HCC re-
section often suffer from high rate of tumor recurrence (Poon
et al., 1999). Other treatment options for patients with inop-
erable HCC are trans-arterial chemoembolization (TACE),
systemic chemotherapies, andmolecular targeted therapy (the
current FDA-approved drug, Sorafenib). It is well known that
most of the HCC patients are refractory to chemotherapies;
thus, the response of these treatments is often not satisfactory.
As such, the 5-year survival rate of HCC remains at approxi-
mately 10–20% over these years (Poon and Fan, 2004).
To improve the clinical outcomes, screening of HCC at
high-risk subjects (hepatitis and cirrhosis groups) allows us to
detect the cancer earlier for effective therapeutic intervention.
Today, the combination of serum alpha-fetoprotein (AFP)
measurement and hepatic ultrasonography are standard
practice for monitoring and/or screening of the malignancy.
However, these methods have limited sensitivity and/or
specificity. Therefore, we have made great efforts to identify
panels of biomarkers for potential clinical applications on
diagnosis and prognosis of HCC. Proteomics is one of the
highly active research areas in biomarker discovery (Feng et al.,
2006; Santamaria et al., 2007; Sun et al., 2007). Our team has
employed a systemic approach for characterizing genetic
and proteomic networks that underlie hepatocarcinogenesis
(Fig. 1). We aim to: (1) identify biomarker for detection of HCC
at early stage, when the tumors can be treated by curative
surgery and/or local ablation therapies; (2) develop molec-
ular tools that can be used to stratify high-risk subgroup of
patients that may be benefited from targeted therapies such as
Sorafenib; and (3) develop newdrugs that can target aggressive
and malignant tumors and show survival advantages. In this
article, we focus on the application of proteomics platform for
discovery of liver cancer biomarkers in Chinese patients, and
provide a brief summary of the candidates for early detection of
HCC and prediction of tumor recurrence (Table 1).
Approach for HCC biomarker discovery
Biomarkers are molecules that are strongly correlated with
physiological states or pathogens, which may be nucleic acids,
proteins, andmetabolites. They can be used in early detection of
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a disease, personalized risk assessment, disease progression
monitoring, and to differentiate responders from nonrespond-
ers to a treatment. The ideal markers should be highly ex-
pressed in the tumor tissues but not in the adjacent nontumor or
normal tissues, and present in the patient’s serum or plasma
samples. Today, AFP is a conventional biomarker of HCC, but
several studies reported that it has a low detection sensitiv-
ity (*50–60%) and its diagnostic accuracy is unsatisfactory
(Sherman, 2001; Stefaniuk et al., 2010; Trevisani et al., 2001).
Hepatic ultrasonography is the standard diagnostic imaging
method for HCC; however, it is highly operator-dependent and
often subjected to high false-negative rate particularly when the
tumor nodule is less than 2 cm in diameter.
To search for HCC biomarkers, we first collected over 200
clinical samples of tumor (TU) and adjacent nontumor (AN)
tissues resected from HCC patients underwent surgery. Most
importantly, each tissue sample also comes with corre-
sponding serum/plasma samples before and after surgery
FIG. 1. Systematic approach to HCC biomarkers and targets discovery. A systematic approach to HCC biomarkers and
targets discovery involves four stages. (1) Clinical specimens such as tumor tissues, peripheral blood mononuclear cells, and
serum samples are collected from HCC patients. (2) To understand how HCC can be differentiated at molecular levels, two-
dimensional (2D) gel electrophoresis is used. Data are analyzed with combination of gene expression data. Also, associations
between the molecular changes and clinical data of patients are analyzed. (3) A target’s biological activities are being studied
in cell lines and animal models for target validation. (4) Finally, the biomarkers or targets are tested in clinical trials before
their uses in clinical settings.
Table 1. Proteomics of HCC for Tumor Classification, Detection, and Prediction of Recurrence
Specimens Platforms Protein biomarkers Study
Classification/
prognostification
Frozen tissues 2-DE MALDI-TOF-MS Heat-shock protein 27,
heat-shock protein 70,
and glucose-regulated
protein 78
Luk et al.,
2006
Frozen tissues 2-DEMALDI-TOF-MS Haptoglobin, cytochrome b5,
progesterone receptor
membrane component 1,
heat shock 27-kDa protein 1,
lysosomal proteinase
cathepsin B, and keratin I
Lee et al., 2009
Serum samples 2-DEMALDI-TOF-MS/
MS
Heat-shock protein 27 Feng et al., 2005
Blood-based
biomarkers
for detection
Frozen tissues 2-DEMALDI-TOF/TOF Lamin B1 Sun et al.,
2010
Frozen tissues 2-DEMALDI-TOF/
TOF
Vimentin Sun et al., 2010
Serum samples SELDI-TOF-MS Five proteomic peaks with
m/z values at 3324, 3394,
4665, 4795, and 5152
Lei et al., 2010
Serum samples SELDI-TOF-MS prothrombin induced
by vitamin K absence-II
Zinkin et al., 2008
Serum Samples SELDI-TOF-MS Six proteomic peaks with
m/z values at 3444, 3890,
4067, 4435, 4470, and 7770
Kanmura et al., 2007
Serum Samples SELDI-TOF-MS Fragmented form
of vitronectin
Paradis et al., 2005
Tumor recurrence Frozen tissues 2-DEMALDI-TOF/TOF Mortalin Yi et al.,
2008
Frozen tissues 2-DE and MS APC-binding protein EB1 Orimo et al., 2008
2-DE, two-dimensional gel electrophoresis; MALDI-TOF-MS, matrix-assisted laser desorption/ionization time time-of-flight mass
spectrometer; SELDI, surface-enhanced laser desorption/ionization.
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from the tissue repository or biobank (Fig. 2) as well as with
detailed demographic and clinicopathological data (Hao et al.,
2009). For proteomics analysis, fresh frozen tissues were
subjected to two-dimensiontal gel electrophoreses (2-DE), and
subsequently the proteomic profiling data were analyzed
using different data-mining algorithms, such as artificial
neural network (ANN) and classification and regression tree
(CART) (Luk et al., 2007). Differentially expressed proteins
were selected for MALDI-ToF/MS analyses. Protein identifi-
cation was further confirmed by qPCR, Western blot and
immunohistochemistry methods on separate set of clinical
samples. Clinical correlation analysis of each candidate pro-
tein biomarker was performed to search for associations with
prognostic outcomes and clinicopahtologic features of pa-
tients such as tumor size, differentiation, staging, vascular
invasion, recurrence, and survival rate (Lee et al., 2007). Next,
we developed immunoassays for measuring the serum bio-
marker levels in HCC patients and control cohorts (healthy
volunteers, hepatitis and non-HCC cirrhosis patients).
Tissue proteome: biomarker set distinguishes HCC
from nonmalignant phenotype
At first, we profiled 67 pairs of tumor and adjacent non-
tumorHCC tissues aswell as 12 normal liver tissues. Themost
striking finding is that certain chaperones or heat-shock pro-
teins (HSPs) are frequently upregulated in the tumor samples,
perhaps reflecting the stress conditions of cancer cells that
need to overcome. We found Hsp27, Hsp70, and glucose-
regulated protein (GRP)78 highly upregulated in HCC, which
also have significant high receiver operating characteristic
curves (ROC) values in distinguishing HCC from nonmalig-
nant tissues. Their expressions profiles were confirmed by
Western blotting and immunohistochemistry.
Aberrant expression of these HSPs was associated with
clinic-pathological parameters, such as AFP level and tumor
venous infiltration (Luk et al., 2006). In fact, other proteomic
studies also revealed the deregulation of HSPs in HCC (Co-
darin et al., 2009; Shen et al., 2006; Zhang et al., 2007).Members
of HSP family have been known to promote tumorigenesis. A
recent study showed that the knockdown of Hsp27 signifi-
cantly suppressed cell migration, invasion, and induced apo-
ptosis in HCC cell lines (Guo et al., 2009). Moreover, a serum
proteome analysis showed that Hsp27 was detected in 90% of
HCC sera but not in normal sera (Feng et al., 2005). These
findings suggest that HSPs have important role in human
cancer, representing promising candidate biomarker for HCC.
Next, we expanded our cohort to 100 pairs of TU/ANHCC
samples for 2-DE profiling analysis, and 80 pairs of the pro-
teomic datasets passed the quality filter criteria (Lee et al.,
FIG. 2. Biobank as the interface between tissue donors and research scientists. Blood and liver tissue samples are collected
from patients. Clinical data such as demographic information (e.g., gender, age, race), clinicopathological information (e.g.,
HBV or HCV infection, serum AFP level, tumor stage), and clinical outcomes (e.g., survival times) are collected from patients
and maintained by biobank. Various technologies such cDNA microarray and two-dimensional (2D) gel electrophoresis are
used to reveal genetic or proteomic changes underlying HCC. The candidate proteins are characterized by matrix assisted
laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) and confirmed by immunohistochemistry
(IHC), Western blotting, or real-time quantitative PCR (RT-qPCR). On the other hand, the 2D gel data are analyzed by
artificial neural network (ANN) and classification and regression tree (CART) models to determine their associations with
prognostic features and outcomes of patients.
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2009). We randomly divided the samples into training and
validation subsets, and used the CART algorithm to analyze
the data. The six protein markers identified in the study in-
clude haptoglobin, cytochrome b5, progesterone receptor
membrane component 1, heat-shock 27-kDa protein 1, lyso-
somal proteinase cathepsin B, and keratin I. These proteins
were used to develop a classifier model for predicting HCC.
Using both the leave-one-out procedure and independent
validation, we found the model has an overall sensitivity and
specificity of 92.5%. Moreover, the protein levels of these
biomarkers are significantly associated with serum AFP, total
protein levels, and the Ishak’s score.
Lamin B1 and vimentin are candidate biomarkers
for early detection of HCC
Today, there are limited studies in revealing biomarkers
that are specific for small-sized HCC. To identify biomarkers
useful for early detection of HCC, we analyzed protein ex-
pression profiles between control subjects andHCC tumors of
different stages (39 HCCs, 20 cirrhosis, and 16 nondiseased
subjects). Twelve proteins were found significantly dysregu-
lated in small-sized (2 cm) tumors—11 proteins (Vimentin;
HSP90; GRP78; Cathepsin D; Lamin B1; Alternative splicing
factor ASF-2; mitochondrial aldehyde dehydrogenase com-
plexed with Nadþ and Mg2 Cys302ser mutant chain H;
Keratin 10; Mitochondrial aldehyde dehydrogenase 2, pre-
cursor; Transferrin; Phosphoinositol 4-phosphate adaptor
protein-2) upregulated and 1 protein (aldehyde dehydroge-
nase 4A1) downregulated. Based on the protein scores, se-
quence coverage, and expression ratios, we subsequently
selected lamin B1 and vimentin for further study on its ap-
plicability to detect early stage and small tumor of HCC, re-
spectively. Interestingly, lamin B1 mRNA was also found in
patients’ plasma as well. The expression of laminB1 was
positively correlated with tumor stages, tumor sizes, and
number of nodules (Sun et al., 2010b). Also, the use of circu-
lating lamin B1 mRNA in plasma could detect early stages of
HCC patients, with 76% sensitivity and 82% specificity.
Vimentin is the second candidate biomarker for early de-
tection of HCC, which was significantly overexpressed in
HCC, particularly in a subgroup of patients with tumor size
less than 2 cm ( p< 0.01). An indirect ELISA assay was devel-
oped using commercially available polyclonal antibody and
in-house purified recombinant protein. We analyzed the se-
rum levels of vimentin in a cohort of 88 HCC patients and 64
control subjects, and found that the vimentin level was sig-
nificantly higher in small tumors than the nonneoplastic con-
trols ( p< 0.01).Moreover, the serumvimentin (at a cutoff level
245ng/mL) had better sensitivity (40.91%) and specificity
(87.55%) than AFP (cutoff level at 100ng/mL; 30.23% sensi-
tivity and 85.19% specificity) in detecting small-size tumors.
Furthermore, combination of the twomarkers can enhance the
detection rate of small HCC to 58.77% sensitivity and 98.15%
specificity (Sun et al., 2010a). Nevertheless, serum vimentin
level is being optimized to enhance the detection rate to 81%.
In the longer term, development of monoclonal antibodies
directed against vimentin isoform(s) that are specific in HCC
would be necessary for more robust and specific biomarker
assays. One study reported that the combined use of AFP,
Lens culinaris agglutinin-reactive AFP (AFP-L3), and pro-
thrombin induced by vitamin K absence-II (PIVKA-II) cor-
rectly identified HCC (2 cm) in 88% of the patients (Zinkin
et al., 2008). Among the eight patientswith tumor size less than
2 cm, seven were identified correctly using the signature.
Vimentin has been widely used as a mesenchymal marker
for epithelial–mesenchymal transition (EMT), a process as-
sociated with malignant progression. Whether vimentin is
solely a marker for EMT or has a function in promoting tumor
progression remains to be elucidated. We hypothesize that
vimentin (in the precursor form or splice isoforms to be de-
termined) is secreted into the circulation during early stages of
tumorigenesis, although further study is needed to reveal the
mechanisms and biological functions.
Serum proteome: circulating markers or proteomic
features for early detection of HCC
For screening purpose, a noninvasive blood test is of par-
amount importance for safety issues and cost effectiveness.
Suspicious subjects can be further examined by needle biopsy
and diagnostic imaging methods. Nevertheless, the current
standard biomarkers are ineffective and inaccurate of diag-
nosing early staged HCC. Of particular, tumor size at 2 cm or
less is extremely difficult to detect in serum samples by cur-
rent biomarker assays or by ex vivo imaging in the tissues.
Indeed, patients with small tumor in early stages can be cured
effectively by surgery and local ablation therapies with good
clinical outcomes.
Surface-enhanced desorption/ionization time-of-flight
mass spectrometry (SELDI-TOF-MS) and ProteinChip tech-
nology require small amount of input material and enable
quantitative measurement of specific protein in a high
throughput manner. These features make them an efficient
and sensitive platform for discovering biomarkers in serum.
Using these technologies, we analyzed serum samples from a
large cohort including 120 HCC patients and 120 chronic
hepatitis-related liver cirrhosis patients. In this study, most of
the HCC samples were obtained from early-staged HCC pa-
tients. We found that the serum SELDI-TOF proteomic sig-
nature, which is based on five proteomic features, in
combination with AFP marker enhanced the detection of
HCC to sensitivity of 95% and specificity of 98%, which
promises to be a good tool for screening of HCC in at-risk
population (Chen et al., 2010). Another study also demon-
strated the capability of using SELDI-TOF-MS in analyzing
serum samples from HBV-related HCC (He et al., 2008). On
the other hand, Paradis et al. (2005) found a fragmented form
of vitronectin as a novel serum marker in HCC, whereas
Kanmura et al. (2007) demonstrated that the protein markers
identified using SELDI-TOF-MS could diagnose six of the
seven patients who had HCC. Although there is a great con-
cern of the experimental variability about the SELDI assay,
we believe that such issues can be resolved if the samples
preparation and assay performance are done according to
well-optimized standard operating procedures in a certified
reference diagnostic laboratories.
Predictive biomarker for HCC recurrence
Tumor recurrence is the main cause of long-term death of
patients with HCC resection, and it is clinically relevant to
identify biomarkers that can predict early tumor recurrence
after surgery or other curative treatments. We used differen-
tial proteomic approach to profile tumorous and matched
264 LUK AND LIU
noncancerous tissues from 103 HCC patients, and found
mortalin (HSP9A) was significantly upregulated in the ‘‘early-
recurrence’’ subgroup of HCC patients. These patients with
high mortalin expression levels had high rate of recurrence
within 1 year after curative surgery. In addition, the mortalin
expression level was associated with vascular invasion and
short disease-free survival time (Yi et al., 2008). Interestingly,
metastatic HCC cell lines showed higher level of mortalin
mRNA compared to the nonmetastatic counterparts or pri-
mary HCC cell lines. It is suggested that mortalin is related to
metastatic property of HCC having a potential clinical utility
for prediction of disease relapse.
Other study employing proteomic profiling of 27 tumor
and 11 adjacent nontumor tissues revealed APC-binding
protein EB1 as an independent prognostic factor for recur-
rence (Orimo et al., 2008). Another report analyzed proteomic
profiles of 12 patients with intrahepatic recurrence within 6
months postsurgery with those of 15 patients who had no
recurrence within 2 years, and the group identified 23 protein
spots that were associated with early intrahepatic recurrence
(Yokoo et al., 2007). These proteins were involved in wide
range of biological processes. It should be noted that patients
recruited in the study are mainly HCV positive, whereas our
HCC cohort is HBV related. Thus, it would be necessary to
determine if those biomarkers are etiology related, and can be
applicable to different ethnic groups.
Conclusion
Proteomic profiling is a powerful tool for discovering novel
biomarkers and identification of new therapeutic targets.
With the advent of the latest proteomic methods such as
Multiple Reaction monitoring (MRM) assay in combination
with Stable Isotope Standards with Capture by Anti-Peptide
Antibodies (SISCAPA), high throughput detection of low-
abundance proteins becomes tangible and feasible. There is a
plethora of biomarkers reported for detecting liver cancer;
however, very few, or none, of them have been validated in
clinical studies. Multicenter validation on a select panel of
biomarkers (in combination with AFP) would be necessary
prior to clinical practice. We believe biomarkers for HCC
detection and risk assessment will be on track to be tested in
prospective, multicenter clinical trial studies.
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